TriSalus Life Sciences Appoints Dr. Richard Marshall as Chief Medical Officer
TLSI sits 24% above its 52-week low of $3.42.
Summary
TriSalus Life Sciences appointed Dr. Richard Marshall as Chief Medical Officer, promoting him internally to lead medical strategy and clinical development for its oncology platform.
Key Events · Executive and Board Changes · TLSI
-
New Chief Medical Officer Appointed
Dr. Richard Marshall, previously Medical Director, has been appointed Chief Medical Officer, effective June 29, 2026.
-
Significant Compensation Package
Dr. Marshall will receive an annual base salary of $525,000, a $250,000 sign-on bonus, and an equity award of 120,000 stock options and 60,000 restricted stock units.
-
Strengthens Clinical Leadership
This appointment is expected to bolster the company's medical strategy and clinical development efforts for its oncology platform, which is critical for a life sciences company.
Analysis · TLSI · Industrial Applications And Services
TriSalus Life Sciences has appointed Dr. Richard Marshall as its new Chief Medical Officer, effective June 29, 2026. Dr. Marshall, previously the Medical Director, brings extensive interventional oncology expertise crucial for advancing the company's PEDD platform and immunotherapeutic development. This strategic leadership appointment strengthens the company's medical strategy at a time when it is navigating financial challenges, as indicated by a recent going concern warning. His compensation package, including a substantial equity award, reflects the importance of this role in driving clinical and strategic initiatives.
At the time of this filing, TLSI was trading at $4.24 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $250.1M. The 52-week trading range was $3.42 to $7.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.